Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.

ABSTRACT:

Objective

This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial.

Study design

Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed.

Results

Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40).

Co

SUBMITTER: Adams-Chapman I 

PROVIDER: S-EPMC8349854 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature